期刊文献+

临床疗效研究中的患者报告结局 被引量:26

Application of Patient-Reported Outcomes in Clinical Research on Therapeutic Efficacy
下载PDF
导出
摘要 随着社会生物心理医学模式的转变,临床评价的方案和指标有了重大转变,患者报告结局(patient-reported outcomes,PROs)日益受到重视。本文介绍了PROs的概念及其测量研究的现况,认为以症状疗效评价为主的中医药临床疗效评价可以借鉴西方的PROs研究模式,建立中医特色的量表评价体系,使中医药疗效评价达到客观化和定量化,为推进中医药的现代化和国际化做出贡献。 Along with the transition of the socio-bio-psycho-medical mode, important change emerges in the program and criterion of clinical assessment, and the patient-reported outcomes (PROs) has been stressed increasingly. The concept of PROs and its current state of research are introduced in this paper. The authors considered that the PROs researching mode, which takes the symptomatic effect evaluation as the main criterion, could be used as reference for the clinical efficacy assessment of Chinese medicine to create a scale evaluating system with Chinese medicine characteristics, for making its more objective and quantitative. It should contribute to the modernization and JnternatJonalizatJon of ChJnese medicine extensively.
作者 陈薇 刘建平
出处 《中国中西医结合杂志》 CAS CSCD 北大核心 2009年第8期746-749,共4页 Chinese Journal of Integrated Traditional and Western Medicine
基金 国家重点基础研究发展计划(973计划)课题资助(No.2006CB504602)
关键词 患者报告结局 中医药 患者报告结局量表 疗效评价 patient-reported outcome Chinese medicine scale of patient-reported outcomes therapeutic effect evaluation
  • 相关文献

参考文献16

  • 1Ware JE, Jr. Scales for measuring general health perceptions [J]. Health Serv Res, 1976, 11 (4): 396- 415.
  • 2Guidance for industry: patient-reported outcome measures: use in medical product development to support labeling claims: draft guidance [ J ]. Health Qual Life Outcomes, 2006, 4:79.
  • 3Fung CH, Hays RD. Prospects and challenges in using patient-reported outcomes in clinical practice [J]. QualLife Res, 2008, 17(10);1297-1302.
  • 4Calkins DR, Rubenstein LU, Cleary PD, et al. Failure of physicians to recognize functional disability in ambulatory patients [J]. Ann Intern Med, 1991, 114 (6) :451-454.
  • 5Boers M, Brooks P, Strand CU, et al. The OMER- ACT filter for outcome measures in rheumatology [J]. J Rheumatol, 1998, 25(2) ;198-199.
  • 6Strand V, Gladman D, Isenberg D, et al. Endpoints: consensus recommendations from OMERACT IV. Outcome Measures in Rheumatology [ J ]. Lupus, 2000, 9(5) :322-327.
  • 7Recommendations for the registration of drugs used in the treatment of rheumatoid arthritis. Group for the Respect of Ethics and Excellence in Science (GREES) : rheumatoid arthritis section [ J ]. Br J Rheumatol, 1998, 37(2):211-215.
  • 8Wenger NK. Assessment of quality of life: a medical imperative [ J ]. Cardiovasc Drugs Ther, 1988, 1 (5) :553-558.
  • 9Kaplan RM. Health-related quality of life in cardiovascular disease [J]. J Consult Clin Psychol, 1988, 56 (3) :382-392.
  • 10Johnson JR, Temple R. Food and drug administration requirements for approval of new anticancer drugs [J]. Cancer Treat Rep, 1985, 69(10) :1155- 1159.

同被引文献277

引证文献26

二级引证文献197

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部